September 3, 2024 – Goldea Capital

PTX Metals Inc. Announces Share Consolidation

Written by Customer Service on September 3, 2024. Posted in Public Companies.

TORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) — PTX Metals Inc. (CSE: PTX) (OTCQB: PANXF, Frankfurt: 9PF) (“PTX Metals” or the “Company”) announces that it will be proceeding with the consolidation of its common shares (the “Common Shares”) on the basis of four (4) pre consolidated Common Shares into one (1) post consolidated Common Share (the “Share Consolidation”) approved by shareholders on July 13, 2022. The Company has made progress in advancing its mineral projects and expects that the Share Consolidation will provide greater flexibility as it continues to develop these projects. Additionally, the Company anticipates that the Share Consolidation will align shareholders for the potential distribution of Common Shares in its subsidiaries. The Company currently has 370,213,062 common shares outstanding, and, accordingly, expects...

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

Written by Customer Service on September 3, 2024. Posted in Public Companies.

LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract was accepted for presentation regarding a clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS Phase 2b/ 3 study at the 2024 Annual NEALS Meeting to be held October 21-24, 2024 (a hybrid meeting in Clearwater, Florida and Online). The presentation will be in poster format and be presented by lead Principal Investigator of the clinical trial, Björn Oskarsson, MD, FAAN, Associate Professor of Neurology at Jacksonville, FL and Director, ALS Center of Excellence. The presentation details are as follows: Submission ID: 164 Title: COMBAT-ALS Phase 2b/3...

Integrated Power Services Acquires Assets of ABB Industrial Services Business

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

Acquisition Adds Electric Motor, Generator, Mechanical, Switchgear & Circuit Breaker Service Centers to IPS’s Growing North American Network IPS President and CEO John Zuleger John Zuleger is president and CEO of Integrated Power Services, a North American leader in the servicing, engineering, and remanufacturing of electrical, mechanical, and power management systems. GREENVILLE, S.C., Sept. 03, 2024 (GLOBE NEWSWIRE) — Integrated Power Services (IPS), a North American leader in the servicing, engineering, and remanufacturing of electrical, mechanical, and power management systems, has finalized the acquisition of ABB’s Industrial Services business, effective August 31, 2024. With locations in Arizona, Indiana, North Carolina, Alberta, and Ontario, ABB Industrial Services provides the highest-quality repair and field...

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances

Written by Customer Service on September 3, 2024. Posted in Public Companies.

MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain cancer. TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1 (LAT1), which is typically over-expressed in GBM. In the first peer-reviewed publication of the IPAX-1 study, Professor Josef Pichler and colleagues report that single or fractionated doses of TLX101 plus EBRT were associated...

Business First Bancshares, Inc. Receives Regulatory Approval of its Merger with Oakwood Bancshares, Inc.

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

BATON ROUGE, La., Sept. 03, 2024 (GLOBE NEWSWIRE) — Business First Bancshares, Inc. (Business First) (Nasdaq: BFST), the holding company for b1BANK, announced it has received all required regulatory approvals and non-objections to complete its merger with Oakwood Bancshares, Inc. (Oakwood), the holding company for Oakwood Bank, a Texas banking association. On August 27, 2024, Oakwood’s shareholders voted to approve the merger. “We appreciate our regulatory partners’ efficient review of the proposed transaction as well as the strong affirmation expressed by the Oakwood shareholder base,” said Jude Melville, chairman, president and CEO of Business First and b1BANK. “We are even more excited about the long-term potential of this relationship than when we first announced it and look forward to together growing b1’s impact across the...

Brookfield Announces Reset Dividend Rate on Its Series 40 Preference Shares

Written by Customer Service on September 3, 2024. Posted in Dividend Reports And Estimates.

All amounts in Canadian dollars unless otherwise stated. BROOKFIELD, NEWS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced that it has determined the fixed dividend rate on its Cumulative Class A Preference Shares, Series 40 (“Series 40 Shares”) (TSX: BN.PF.F) for the five years commencing October 1, 2024 and ending September 30, 2029. If declared, the fixed quarterly dividends on the Series 40 Shares during the five years commencing October 1, 2024 will be paid at an annual rate of 5.833% ($0.3645625 per share per quarter). Holders of Series 40 Shares have the right, at their option, exercisable not later than 5:00 p.m. (Toronto time) on September 16, 2024, to convert all or part of their Series 40 Shares, on a one-for-one basis, into Cumulative Class A Preference Shares,...

Guardian Capital Group Limited completes its acquisition of Galibier Capital Management Ltd.

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

TORONTO, Sept. 03, 2024 (GLOBE NEWSWIRE) — Guardian Capital Group Limited (Guardian) (TSX: GCG; GCG.A) announced today that it has completed its acquisition of Galibier Capital Management Ltd. (Galibier), a Toronto, Canada-based investment management firm. Guardian completed the transaction on the terms announced on June 20, 2024. The addition of Galibier increases Guardian’s assets under management by approximately C$1 billion and adds a team of high-quality, experienced investment professionals focused on fundamental equity research and valuation. “We are truly pleased that Galibier founder, Joe Sirdevan, and his team are joining Guardian and look forward to jointly building on the opportunities ahead. There is a good cultural alignment between the firms, and we welcome incorporating Galibier’s distinctive investment approach...

Ascendis Pharma Reports Second Quarter 2024 Financial Results

Written by Customer Service on September 3, 2024. Posted in Earnings Releases And Operating Results.

YORVIPATH approved by U.S. Food & Drug Administration (FDA) as the first and only treatment of hypoparathyroidism in adults TransCon CNP (navepegritide) pivotal ApproaCH Trial topline results expected in the coming weeks SKYTROFA Q2 revenue of €26 million – 134% year-over-year volume growth offset by negative adjustment of €27 million, resetting market access for continued growth Revising full year 2024 SKYTROFA revenue outlook to €220 – €240 million Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2024, and provided a business update. “The recent FDA approval of YORVIPATH demonstrates why our unrelenting focus on helping patients suffering from hypoparathyroidism and...

BrightSpring Health Services Announces Definitive Agreement to Acquire Haven Hospice, Expanding Hospice Services into Florida

Written by Customer Service on September 3, 2024. Posted in Mergers And Acquisitions.

LOUISVILLE, Ky., Sept. 03, 2024 (GLOBE NEWSWIRE) — BrightSpring Health Services (“BrightSpring” or “the Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced that it completed the acquisition of the assets of North Central Florida Hospice, Inc. and Haven Medical Group, LLC (collectively “Haven Hospice”), a Florida-based company holding a Certificate of Need (CON) for comprehensive hospice care services in 18 counties in north central Florida, effective September 1, 2024. “We are excited to welcome Haven Hospice into BrightSpring, expanding our existing hospice services into the CON state of Florida,” said BrightSpring’s President and CEO Jon Rousseau. “The delivery of compassionate hospice care is critical for patients and their families, and we’re committed...

Guggenheim Investments Announces September 2024 Closed-End Fund Distributions

Written by Customer Service on September 3, 2024. Posted in Dividend Reports And Estimates.

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) — Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund (collectively, the “Funds” and each, a “Fund”). The following dates apply to the distributions: Record Date September 13, 2024 Ex-Dividend Date September 13, 2024 Payable Date September 30, 2024 Distribution Schedule NYSE Ticker Closed-End Fund Name Distribution Per Share Change from Previous Distribution Frequency AVK Advent Convertible and Income Fund $0.1172† Monthly GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust $0.12573† Monthly GOF Guggenheim Strategic Opportunities Fund $0.1821† Monthly GUG Guggenheim Active Allocation Fund $0.11875† Monthly †...

Day: September 3, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice